Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
Canada · Delayed Price · Currency is CAD | Market Cap | 682.79M +153.2% |
| Revenue (ttm) | n/a |
| Net Income | -74.81M |
| EPS | -1.42 |
| Shares Out | 65.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 102,734 |
| Open | 10.35 |
| Previous Close | 10.36 |
| Day's Range | 10.26 - 11.64 |
| 52-Week Range | 7.15 - 12.86 |
| Beta | 1.50 |
| Analysts | Strong Buy |
| Price Target | 16.00 (+37.46%) |
| Earnings Date | Nov 5, 2026 |
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company’s product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the ... [Read more]
Analyst Summary
According to 11 analysts, the average rating for EPRX stock is "Strong Buy." The 12-month stock price target is $16.00, which is an increase of 37.46% from the latest price.
News
Eupraxia Pharmaceuticals management to meet with Oppenheimer
Meeting to be held on September 9 hosted by Oppenheimer.
Eupraxia Pharmaceuticals Registration statement: Registration filing
Eupraxia Pharmaceuticals filed a registration statement on August 19, 2026, providing details about a securities offering with the SEC.
Eupraxia Pharmaceuticals reports Q2 net income ($14.5M) vs ($8.7M) last year
“Eupraxia is well funded with the experienced talent to execute on key upcoming milestones, including the Phase 2b Eosinophilic Esophagitis (EoE) trial with interim data expected to be released in…
Eupraxia Pharmaceuticals announces results from RESOLVE study analysis
Eupraxia Pharmaceuticals (EPRX) announced results from a new analysis of the RESOLVE study examining the effect of EP-104GI on symptom severity, including for the first time an analysis of the…
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post trea...
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI
Eupraxia Pharmaceuticals Earnings release: Q2 2026
Eupraxia Pharmaceuticals released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Eupraxia Pharmaceuticals Registration statement: Q2 2026
Eupraxia Pharmaceuticals filed a registration statement on August 11, 2026, providing details about a securities offering with the SEC.
Eupraxia Pharmaceuticals Registration statement: Q2 2026
Eupraxia Pharmaceuticals filed a registration statement on August 11, 2026, providing details about a securities offering with the SEC.
Eupraxia Pharmaceuticals Registration statement: Registration filing
Eupraxia Pharmaceuticals filed a registration statement on August 6, 2026, providing details about a securities offering with the SEC.
Eupraxia Pharmaceuticals files $300M mixed securities shelf
06:12 EDT Eupraxia Pharmaceuticals (EPRX) files $300M mixed securities shelf
Eupraxia Pharmaceuticals Slides: Investor presentation
Eupraxia Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on July 30, 2026.
Eupraxia chief scientific and operating officer Amanda Malone steps down
Eupraxia Pharmaceuticals (EPRX) announced Amanda Malone has stepped down from her role as chief scientific and operating officer, effective July 10. Eupraxia is grateful for her years of expertise in…
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth
VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging...
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization
VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging i...
Oppenheimer starts Eupraxia at Outperform, sees upside from EoE
Oppenheimer analyst Jay Olson initiated coverage of Eupraxia Pharmaceuticals (EPRX) with an Outperform rating and $17 price target The firm said its price target reflects the differentiated potential ...
Eupraxia Pharmaceuticals initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Eupraxia Pharmaceuticals (EPRX) with an Outperform rating and $17 price target
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders
VANCOUVER, British Columbia, June 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging...
Eupraxia Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
A novel, long-acting injectable therapy for EoE shows strong efficacy and safety, with up to 80% clinical remission at six months and sustained benefits for a year. Expansion into related GI conditions and a robust financial runway support continued development and upcoming pivotal trials.
Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging it...
Eupraxia Pharmaceuticals initiated with a Buy at Stifel
Stifel initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Buy rating and $25 price target Eupraxia is validating its Diffusphere platform starting with a well-known corticosteroid, fluticaso...
Eupraxia Pharmaceuticals Slides: Corporate presentation
Eupraxia Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
Eupraxia Pharmaceuticals reports Q1 net loss ($12.7M) vs. ($6.8M) last year
The Company had cash and cash equivalents of $58.5M and short-term investments of $80.4M as of March 31, up from a cash balance of $80.6M at the end of the…
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indicat...
Eupraxia Pharmaceuticals Earnings release: Q1 2026
Eupraxia Pharmaceuticals released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.